http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020
-
Corbus Pharma (CRBP) Reports Publication of Results from Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial
-
Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology
-
Corbus Announces Publication of Lenabasum Systemic Sclerosis Double-Blind, Placebo-Control Phase 2 Clinical Trial Results in Arthritis & Rheumatology
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2019 Financial Results
-
Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director
-
Corbus Pharmaceuticals Announces Changes to its Board and Appointment of Pete Salzmann, M.D. as Independent Director
-
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020
-
Corbus Pharmaceuticals to Report Fourth Quarter and Year-End 2019 Results on March 12, 2020
-
Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System
-
Corbus Pharmaceuticals to Host Expert Symposium on the Therapeutic Potential of Targeting the Endocannabinoid System
-
Corbus Pharma (CRBP) Reports Complete Enrollment of Ph. 2b Study of Lenabasum for Treatment of Cystic Fibrosis
-
Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
-
Corbus Pharmaceuticals Completes Enrollment of Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis
-
Corbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London
-
Corbus Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference in London
-
Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting
-
Corbus Pharmaceuticals Updates Data from Lenabasum Open-Label Extension Studies in Systemic Sclerosis and Dermatomyositis at 2019 ACR Annual Meeting
-
Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates
-
Corbus Pharmaceuticals Reports 2019 Third Quarter Financial Results and Provides Clinical and Corporate Updates
-
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Operational and Financial Results on November 7, 2019
-
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2019 Operational and Financial Results on November 7, 2019
-
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting
-
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2019 ACR Annual Meeting
-
Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates
-
Corbus Pharmaceuticals Reports 2019 Second Quarter Financial Results and Provides Clinical and Corporate Updates
-
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Operational and Financial Results on August 8, 2019
-
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Operational and Financial Results on August 8, 2019
-
Corbus Pharmaceuticals to Host 2019 R&D Day in New York City
-
Corbus Pharmaceuticals to Host 2019 R&D Day in New York City
-
Corbus Pharma (CRBP) Says Lenabasum Open-Label Extension Data to be Presented at EULAR Continue to Show Favorable Safety Profile and Improvement in Efficacy Outcomes
-
Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Stu
-
Lenabasum Open-Label Extension Data to be Presented at EULAR 2019 Continue to Show a Favorable Safety Profile and Improvement in Efficacy Outcomes in Systemic Sclerosis and Dermatomyositis Phase 2 Stu
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in June
-
Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting
-
Corbus Pharmaceuticals Announces Presentation of Six Abstracts at EULAR 2019 Annual Meeting
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May
-
Corbus Pharmaceuticals to Present at Two Upcoming Investor Conferences in May
-
Corbus Pharmaceuticals Reports 2019 First Quarter Financial Results and Provides Clinical Updates
-
Corbus Pharmaceuticals Reports 2019 First Quarter Financial Results and Provides Clinical Updates
-
Corbus Pharma (CRBP) Reports Complete Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
-
Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
-
Corbus Pharmaceuticals Completes Enrollment of RESOLVE-1 Phase 3 Study of Lenabasum for Treatment of Systemic Sclerosis
-
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019
-
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019
-
Corbus Pharma (CRBP) Reports Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study Following Meeting with FDA
-
Corbus Pharmaceuticals Announces Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study in Systemic Sclerosis in U.S. to ACR CRISS from mRSS Following Meeting with FDA
-
Corbus Pharmaceuticals Announces Change of Primary Endpoint in Ongoing RESOLVE-1 Phase 3 Study in Systemic Sclerosis in U.S. to ACR CRISS from mRSS Following Meeting with FDA

